col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


27 Results       Page 1

 [1] 
SAGE Publications: Clinical Trials
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―17 Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance Matthew J Gooden, Gina Norato, Katherine Landry, Sandra B Martin, Avindra Nath, Lauren Reoma
2 [GO] 2023―Dec―23 A pilot recruitment strategy to enhance ethical and equitable access to Covid-19 pediatric vaccine trials William J Muller, Ravi Jhaveri, Taylor Heald-Sargent, Michelle L Macy, Nia Heard-Garris, Seema Shah, Erin Paquette
3 [GO] 2023―Nov―20 Evaluating whether the proportional odds models to analyse ordinal outcomes in COVID-19 clinical trials is providing clinically interpretable treatment effects: A systematic review Masuma Uddin, Nasir Z Bashir, Brennan C Kahan
4 [GO] 2023―Feb―11 Adapting international clinical trials during COVID-19 and beyond Kamala Thriemer, Tamiru Shibiru Degaga, Mohammad Shafiul Alam, Bipin Adhikari, Rupam Tripura, Mohammad Sharif Hossain, et al. (+16)
5 [GO] 2023―Feb―06 Is it reasonable to label a trial as pragmatic whose investigatorsdo not? The UK RECOVERY COVID-19 trial case Rafael Dal-Ré
6 [GO] 2022―Dec―23 Navigating COVID-19 and related challenges to completing clinical trials: Lessons from the PATRIOT and STEP-UP randomized prevention trials Priscilla K Salovaara, Christine Li, Andrew Nicholson, Stuart R Lipsitz, Sundar Natarajan
7 [GO] 2022―Jul―27 Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters Victor DeGruttola, Ravi Goyal, Natasha K Martin, Rui Wang
8 [GO] 2022―Jul―02 Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges Susan Halabi, Jinyi Zhou, Yijie He, Linda R Bressler, Adrian F Hernandez, Nicholas A Turner, Hwanhee Hong
9 [GO] 2021―Oct―11 Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) Daniel D Murray, Abdel G Babiker, Jason V Baker, Christina E Barkauskas, Samuel M Brown, Christina C Chang, et al. (+22)
10 [GO] 2021―Jul―03 What do we do with our under-enrolled single-center COVID-19 clinical trials? Shing M Lee, Denise Esserman, Ken Cheung, James Dziura, Peter Peduzzi, Magdalena Sobieszczyk
11 [GO] 2021―Jun―22 Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom M Estée Török, Benjamin R Underwood, Mark Toshner, Claire Waddington, Emad Sidhom, Katherine Sharrocks, et al. (+75)
12 [GO] 2021―May―27 COVID-19 vaccine trials: The potential for “hybrid” analyses Thomas R Fleming, Martha Nason, Philip R Krause, Ira M Longini, Ana-Maria Henao-Restrepo
13 [GO] 2021―May―20 A telehealth-based randomized controlled trial: A model for outpatient trials of off-label medications during the COVID-19 pandemic Salomeh Keyhani, J Daniel Kelly, Stephen Bent, W John Boscardin, Michael G Shlipak, Sam Leonard, et al. (+10)
14 [GO] 2021―Feb―10 An ethics framework for consolidating and prioritizing COVID-19 clinical trials Michelle N Meyer, Luke Gelinas, Barbara E Bierer, Sara Chandros Hull, Steven Joffe, David Magnus, et al. (+6)
15 [GO] 2021―Feb―09 Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape Haley Hedlin, Ariadna Garcia, Yingjie Weng, Ziyuan He, Vandana Sundaram, Bryan Bunning, et al. (+7)
16 [GO] 2021―Feb―09 COVID-19 vaccine trials: The use of active controls and non-inferiority studies Thomas R Fleming, Philip R Krause, Martha Nason, Ira M Longini, Ana-Maria M Henao-Restrepo
17 [GO] 2021―Feb―05 Commentary on Meyers et al: Ethically prioritizing trials in the COVID-19 era - practical considerations Romana Hasnain-Wynia, Matthew DeCamp, Marilyn Coors
18 [GO] 2021―Jan―21 Reopening schools safely in the face of COVID-19: Can cluster randomized trials help? Charles Weijer, Karla Hemming, Spencer Phillips Hey, Holly Fernandez Lynch
19 [GO] 2020―Dec―16 Lack of harmonization of coronavirus disease ordinal scales Deborah A Zarin, Stephen Rosenfeld
20 [GO] 2020―Nov―24 Experience of conducting clinical trials of investigational medicinal products during a respiratory virus pandemic: Lessons learnt from COVID-19 James E Burns, Ffion E Carlin
21 [GO] 2020―Aug―20 Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial Brett L Houston, Patrick R Lawler, Ewan C Goligher, Michael E Farkouh, Charlotte Bradbury, Marc Carrier, et al. (+21)
22 [GO] 2020―Aug―20 COVID-19 impact on multi-site recruitment and enrollment Emma Strujo, Mechelle Sanders, Kevin Fiscella, Marie Thomas, Brent Johnson, Alex Deets, et al. (+7)
23 [GO] 2020―Aug―20 A concern about survival time as an endpoint in coronavirus disease 2019 clinical trials Kay See Tan
24 [GO] 2020―Jul―17 Endpoints for randomized controlled clinical trials for COVID-19 treatments Lori E Dodd, Dean Follmann, Jing Wang, Franz Koenig, Lisa L Korn, Christian Schoergenhofer, et al. (+9)
25 [GO] 2020―Jul―15 Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic Steven Piantadosi
26 [GO] 2020―Jul―11 Editorial: Clinical trial design in the era of COVID-19 Colin B Begg, Mithat Gonen, Daniel F Heitjan
27 [GO] 2020―Jul―11 Clinical trials in the time of a pandemic Susan S Ellenberg
 [1] 

27 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec